CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
EP: 1.What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
EP: 2.NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
EP: 3.Induction Therapy Regimens for Transplant-Eligible NDMM
EP: 4.Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
EP: 5.Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 6.Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
EP: 7.Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
EP: 8.Patient Scenario: Treatment Options in MM at First Relapse
EP: 9.Factors in Selecting Therapy at First Relapse in Multiple Myeloma
EP: 10.Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
EP: 11.Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
EP: 12.Bispecifics in Multiple Myeloma: Dosing and Transition of Care
EP: 13.Combination Strategies With Bispecifics in Multiple Myeloma
EP: 14.Bispecifics in Multiple Myeloma: Adverse Event Management
Now Viewing
EP: 15.CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
EP: 16.Multiple Myeloma: Unmet Needs and Future Directions in Care
Related Videos
Related Content
